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A series of macrocyclic derivatives 2-6 were prepared using Nα-dinicotinoyl-bis[L-phenylalaninyl-L-leucyl]hydrazide 1 
and cyclo pentapeptide hydrazide 2 as starting materials. The hydrazide 1 was cyclized with diaminoalkanes to macrocyclic 
hezaazahexaamide derivatives 3a-c, respectively. Finally, compound2 was condensed with 3,5-diacetylpyridine gave the 
corresponding macrocyclic Schiff base 4. Finally, condensation of 2 with substituted aromatic or heterocyclic aldehyde 
derivatives gave the corresponding Schiff base derivatives 5a-f and 6a-c, respectively. The synthesized compounds were 
screened as 5α-reductase inhibitors and anti-proliferative activity against prostate cancer cell lines. 
Keywords: Macrocyclic pentapeptide, Schiff bases, 5α-reductase inhibitors and anti-proliferate activities. 
Introduction 
Peptides are formed from the chemical reaction 
between two or more amino acids by different 
methods
1
 and the covalent chemical bonds are formed 
when the carboxyl group of one amino acid reacts with 
the amino group of another. Interestingly, some 
individual amino acids exemplified by valine, leucine, 
iso-leucine, and phenylalanine were reported to have 
biological and pharmacological properties in different 
experimental models
2
. In previous work, we have 
found that certain substituted heterocyclic compounds 
show antimicrobial
3
, anti-viral
4
, and reductase 
inhibitors
5
. On the other hand, some heterocyclic 
pyridine derivatives have promising biological
6
 and 
anticancer activity
7
. Recently, in our previous work, 
some of peptidopyridine derivatives have been 
synthesized
8,9
 and tested as pharmacological activity
10
, 
analgesic and anti-inflammatory
11
, antimicrobial
12,13
, 
antiparkinsonian
14
, anticancer
15,16
 agents. In view of 
these observations and in continuation of our previous 
work in pyridine and peptide chemistry, we 
synthesized some new macrocyclic pyridine 
pentapeptide compounds and screened as 5α-reductase 
inhibitors and anti-proliferative activity against prostate 
cancer cell lines.  
 
Materials and methods 
Melting points were determined in open glass 
capillary tubes with an Electro Thermal Digital 
melting point apparatus (model: IA9100) and are 
uncorrected. Elemental microanalysis for carbon, 
hydrogen and nitrogen (Microanalytical Unit, NRC) 
was found within the acceptable limits of the 
calculated values. Infrared spectra (KBr) were 
recorded on a Nexus 670 FTIR Nicolet, Fourier 
Transform infrared spectrometer. Proton and carbon 
nuclear magnetic resonance (
1
H- and 
13
C NMR) 
spectra were run in (DMSO-d6) on Jeol 500 MHz 
instruments “500 MHz to 1HNMR and 125 MHz to 
13CNMR”. Mass spectra were run on a MAT Finnigan 
SSQ 7000 spectrometer, using the electron impact 
technique (EI). Analytical thin layer chromatography 
———— 
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(TLC) was performed on silica gel aluminum sheets, 
60F254 (E. Merck). 
 
Synthesis of cyclo-(Nα-dinicotinoyl)-bis[L-phenylalaninyl-L-
leucyl]aliphatic diamines (3a-c) 
To a stirred solution of hydrazide (1)
8,17,18
 (1 mmol) 
a mixture of 5N HCl (2 ml), AcOH (3 ml) and H2O 
(10 ml) at -5
o
Cfor 15 min, sodium nitrite (0.2 g, 2 ml 
water) was added. The reaction mixture was stirred 
for 0.5 h, then extracted with cold dichloromethane  
(-5
o
C), which was added to aliphatic diamine,  
namely, 1,3-propanediamine, 1,4-butanediamine or 
1,6-hexanediamine (1 mmol, 10 mL dichloromethane) 
with stirring for 3 h at -5
o
C, then at room temperature 
for 20 h. The mixture product washed with water,  
0.5 N hydrochloric acid, water and dried over 
anhydrous calcium chloride. The solvent was 
evaporated to dryness, the crude residue were purified 
by preparative chromatography on silica gel by using 
chloroform/ethanol (9:1, v/v) as eluent to give the 
corresponding macrocyclic trtrapeptide derivatives 
3a-c,respectively. 
3a:Yield 65%; m.p. 206-208°C. []
25
D
 = -106  
(c = 0.5, DMF). IR (film): ν = 3448-3345 (NH), 1654, 
1534, 1254 (3C=O, amides) cm
-1
. 
1
H NMR:δ = 0.88-
0.95 (m, 12H, 4CH3), 1.72-1.80 (m, 6H, 3CH2), 2.22-
2.36 (m, 2H, 2CH), 3.30 (t, 4H, 2CH2), 3.44 (d, 4H, 
2CH2), 4.25-4.32 (m, 2H, 2CH), 4.68-4.72 (m, 2H, 
2CH), 6.95-7.75 (m, 10H, Ar-H), 8.36 s, 9.05 (s, 3H, 
pyr-H), 8.66, 8.86, 9.20 (3s, 6H, 6NH, 
D2Oexchangeable). 
13
C NMR: δ = 18.90, 19.40, 
24.00, 32.65, 38.80, 39.40, 42.18, 52.90, 54.24, 
125.80, 127.50, 128.32, 131.50, 138.75, 141.12, 
152.35, 166.72, 169.85, 172.96 (40 C). MS (EI, 70 
eV): m/z (%) = 726 (13) [M]
+
. C40H51N7O6 (725.87): 
Calcd. C 66.19, H 7.08, N 13.51; found C 66.05, H 
7.00, N 13.40. 
3b:Yield 74%; m.p. 196-198°C. []
25
D
 = -118 (c = 
0.5, DMF). IR (film): ν = 3424-3365 (NH), 1658, 1536, 
1240 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.86-0.95 (m, 
12H, 4 CH3), 1.28-1.36 (m, 4H, 2 CH2), 1.40-1.45 (m, 
4H, 2 CH2), 1.68-1.74 (m, 4H, 2 CH2), 2.26-2.34 (m, 
2H, 2CH), 3.36 (d, 4H, 2CH2), 4.15-4.24 (m, 4H, 4 CH), 
6.98-7.54 (m, 10H, 2Ph-H), 8.48, 9.05 (s, 3H, pyr-H), 
8.80, 8.92, 9.16 (3s, 6H, 6NH, D2Oexchangeable).
13
C 
NMR: δ = 19.20, 19.45, 23.95, 28.82, 32.68, 39.42, 
42.24, 52.86, 54.36, 125.82, 127.55, 128.36, 131.65, 
138.74, 141.18, 152.34, 166.75, 169.80, 172.84 (41C). 
MS (EI, 70 eV): m/z (%) = 740 (13) [M]
+
. C41H53N7O6 
(739.90): Calcd. C 66.55, H 7.22, N 13.25; found C 
66.45, H 7.16, N 13.22. 
3c: Yield 70%; m.p. 232-234°C. []
25
D
 = -98  
(c = 0.5, DMF). IR (film): ν = 3410-3355 (NH), 1660, 
1534, 1245 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.86-
0.92 (m, 12H, 4 CH3), 1.24-1.26 (m, 4H, 2 CH2), 
1.32-1.35 (m, 4H, 2CH2), 1.42-1.46 (m, 4H, 2 CH2), 
1.62-1.70 (m, 4H, 2 CH2), 2.26-2.35 (m, 2H, 2CH), 
3.44 (d, 4H, 2CH2), 4.18-4.24 (m, 4H, 4 CH), 7.00-
7.65 (m, 10H, 2Ph-H), 8.42, 9.08 (2s, 3H, pyridyl-H), 
8.75, 8.93, 9.16 (3s, 6H, 6NH, D2Oexchangeable). 
13
C 
NMR: δ = 18.95, 19.32, 23.90, 27.82, 32.68, 40.56, 
39.48, 42.56, 52.80, 54.34, 125.80, 127.58, 128.34, 
138.75, 131.64, 141.24, 152.35, 166.74, 168.98, 
172.80 (43C). MS (EI, 70 eV): m/z (%) = 768 (16) 
[M]
+
. C43H57N7O6 (767.95): Calcd. C 67.25, H 7.48, N 
12.77; found C 67.14, H 7.41, N 12.68. 
 
Synthesis of compound4 
A mixture of 3,5-bis-hydrazide 1 (1 mmol) and 3,5-
diacetylpyridine(0.163 g, 1 mmol) in AcOH (25 mL) 
was refluxed for 4 h. The reaction mixture was poured 
into ice water, the obtained solid was collected by 
filtration, washed with water and crystallized  
from AcOH/H2O to give bicyclic product 4.Yield  
70%; m.p. 248-250°C. []
25
D
 = -98 (c = 0.5, DMF). IR 
(film): ν = 3430-3355 (NH), 1654, 1534, 1252 (3C=O, 
amides) cm
-1
. 
1
H NMR: δ = 0.90-0.96 (m, 18H, 6CH3), 
1.68-1.74 (m, 4H, 2CH2), 2.22-2.30 (m, 2H, 2CH), 
3.44 (d, 4H, 2CH2), 4.20-4.30 (m, 2H, 2CH), 4.65-4.75 
(m, 2H, 2CH), 6.96-7.70 (m, 10H, 2Ph-H), 8.20-8.25 
(m, 3H, pyr-H), 8.46, 9.08 (2s, 3H, pyr-H), 8.75, 8.85, 
9.16 (3s, 6H, 6NH, D2Oexchangeable). 
13
C NMR:  
δ = 13.55, 17.96, 18.45, 23.72, 40.70, 42.42,  
52.62, 53.18, 124.28, 128.44, 129.45, 138.80, 155.56, 
126.12, 131.74, 135.88, 140.52, 152.45, 154.55, 
163.85, 169.35, 178.55 (46 C). MS (EI, 70 eV):  
m/z (%) = 842 (34) [M-1]
+
. C46H54N10O6 (842.98): 
Calcd. C 65.54, H 6.46, N 16.62; found C 65.40,  
H 6.38, N 16.50. 
 
Synthesis of Schiff base derivatives 5a-cand 6a-c 
A mixture of 2 (1 mmol) and substituted  
aromatic aldehydes “benzaldehyde, p-methyl-, orp-
methoxybenzaldehyde” or heterocyclic aldehydes,  
“2-, 3-, or 4-pyridinecarbaldehydes” (1 mmol) in 
absolute ethanol (25 mL) in the presence of a mixture 
of TEA/DEA (4 ml, 2:2) was refluxed for 4-6 h. The 
solvent was concentrated to dryness and the obtained 
residue was solidified with ether, filtered off, washed 
with ether and crystallized from the proper solvents to 
afford pentapeptide hydrazone derivatives 5a-cand 
6a-c,respectively. 
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5a:Yield 65%; m.p. 210-212°C. []
25
D
 = -118  
(c = 0.5, DMF). IR (film): ν = 3425-3356 (NH), 1655, 
1533, 1234 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.86-
0.92 (m, 12H, 4CH3), 1.28-1.40 (m, 4H, 2CH2), 1.55-
1.65 (m, 4H, 2 CH2), 2.22-2.30 (m, 2H, 2CH), 3.15-
3.25 (m, 2H, CH2), 3.45 (d, 4H, 2CH2), 4.00-4.10  
(m, 4H, 4CH), 4.42-4.46 (m, 1H, CH), 6.96-7.60 (m, 
16H, 3Ph-H + CH=N),8.38, 9.02 (2s, 3H, pyr-H), 8.56, 
8.75, 8.86, 9.25 (3s, 7H, 7 NH, D2Oexchangeable); 
13
C 
NMR: δ = 17.75, 18.12, 28.32, 30.36, 38.05, 23.75, 
40.92, 41.74, 52.25, 52.85, 58.45, 124.35, 128.35, 
128.65, 129.15, 129.45, 131.05, 133.55, 138.71, 
142.75, 131.44, 140.14, 152.22, 163.80, 169.18, 
170.63, 176.74 (49C). MS (EI, 70 eV): m/z (%) = 886 
(16) [M]
+
. C49H59N9O7 (886.04): Calcd. C 66.42, H 
6.71, N 14.23; found C 66.28, H 6.58, N 14.12. 
5b:Yield 70%; m.p. 232-234°C. []
25
D
 = - 98  
(c = 0.5, DMF). IR (film): ν = 3455-3325 (NH), 1652, 
1531, 1233 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.90-
0.95 (m, 12H, 4CH3), 1.22-1.40 (m, 4H, 2CH2), 1.56-
1.68 (m, 4H, 2 CH2), 2.18-2.30 (m, 2H, 2CH), 2.40 (s, 
3H, CH3), 3.15-3.25 (m, 2H, CH2), 3.50 (d, 4H, 
2CH2), 4.02-4.16 (m, 4H, 4CH), 4.46-4.50 (m, 1H, 
CH), 7.00-7.64 (m, 15H, 3Ph-H + CH=N),8.50, 9.10 
(2s 3H, pyr-H), 8.60, 8.82, 8.90, 9.24 (4s, 7H, 7 NH, 
D2Oexchangeable). 
13
C NMR: δ = 17.84, 18.54, 
24.18, 28.37, 30.36, 38.15, 23.74, 40.94, 41.74, 52.30, 
52.80, 58.35, 126.00, 127.48, 128.35, 129.06, 129.24, 
130.16, 138.90, 140,43, 142.70, 131.46, 140.34, 
152.25, 163.80, 169.18, 170.60, 176.90 (50C). MS 
(EI, 70 eV): m/z (%) = 900 (22) [M]
+
. C50H61N9O7 
(900.07): Calcd. C 66.72, H 6.83, N 14.01; found C 
66.64, H 6.70, N 13.94. 
5c:Yield 72%; m.p. 244-246°C. []
25
D
 = - 106  
(c = 0.5, DMF). IR (film): ν = 3418-3350 (NH), 1654, 
1532, 1235 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.90-
0.96 (m, 12H, 4CH3), 1.20-1.34 (m, 4H, 2CH2), 1.55-
1.60 (m, 4H, 2 CH2), 2.22-2.34 (m, 2H, 2CH), 3.16-
3.24 (m, 2H, CH2), 3.44 (d, 4H, 2CH2), 3.72 (s, 3H, 
OCH3), 4.02-4.15 (m, 4H, 4CH), 4.40-4.46 (m, 1H, 
CH), 6.98-7.60 (m, 15H, 3Ph-H + CH=N),8.44, 9.12 
(2s, 3H, pyr-H), 8.56, 8.76, 8.85, 9.24 (4s, 7H, 7 NH, 
D2Oexchangeable). 
13
C NMR: δ = 17.86, 18.42, 
28.30, 30.30, 38.00, 23.72, 40.90, 41.80, 52.26, 52.84, 
55.74, 58.40, 114.45, 124.45, 125.45, 128.36, 129.34, 
129.70, 138.75, 162,46, 142.65, 131.50, 140.20, 
152.18, 163.82, 169.20, 170.62, 176.34 (50C). MS 
(EI, 70 eV): m/z (%) = 916 (20) [M]
+
. C50H61N9O8 
(916.07): Calcd. C 65.56, H 6.71, N 13.76, found C 
65.46, H 6.60, N 13.68. 
6a:Yield 65%; m.p. 246-248°C. []
25
D
 = -104  
(c = 0.5, DMF). IR (film): ν = 3410-3340 (NH), 1655, 
1535, 1235 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.86-
0.95 (m, 12H, 4CH3), 1.22-1.34 (m, 4H, 2CH2), 1.55-
1.70 (m, 4H, 2 CH2), 2.24-2.32 (m, 2H, 2CH), 3.15-
3.26 (m, 2H, CH2), 3.45 (d, 4H, 2CH2), 4.00-4.12 (m, 
4H, 4CH), 4.40-4.46 (m, 1H, CH), 7.12-7.29 (m, 10H, 
2Ph-H), 7.39-8.20 (m, 5H, pyr-H + CH=N),8.45, 9.12 
(2s, 3H, pyr-H), 8.58, 8.74, 8.86, 9.45 (4s, 7H, 7 NH, 
D2Oexchangeable). 
13
C NMR: δ = 17.64, 17.94, 
28.38, 30.36, 38.08, 23.86, 40.95, 41.74, 52.35, 52.85, 
58.45, 119.34, 125.12, 135.65, 148,65, 152.98, 
124.98, 127.60, 128.68, 136.16, 143.82, 131.55, 
140.15, 152.15, 165.54, 169.45, 170.76, 175.12 
(48C). MS (EI, 70 eV): m/z (%) = 886 (35) [M]
+
. 
C48H58N10O7 (887.06): Calcd. C 64.99, H 6.59, N 
15.79; found C 64.90, H 6.52, N 15.72. 
6b:Yield 60%; m.p. 225-227°C. - []
25
D
 = 118  
(c = 0.5, DMF). IR (film): ν = 3424-3345 (NH), 1652, 
1533, 1234 (3C=O, amides) cm
-1
. 
1
H NMR: δ = 0.90-
0.96 (m, 12H, 4CH3), 1.24-1.32 (m, 4H, 2CH2), 1.52-
1.67 (m, 4H, 2 CH2), 2.25-2.30 (m, 2H, 2CH), 3.18-
3.25 (m, 2H, CH2), 3.48 (d, 4H, 2CH2), 4.04-4.10 (m, 
4H, 4CH), 4.38-4.45 (m, 1H, CH), 7.15-7.32 (m, 10H, 
2Ph-H), 7.54-8.40 (m, 3H, pyr-H), 8.65 (s, 1H, 
CH=N),8.48, 9.02, 9.14 (3s, 4H, pyr-H), 8.56, 8.78, 
8.82, 9.46 (4s, 7H, 7 NH, D2Oexchangeable). 
13
C 
NMR: δ = 17.74, 17.90, 28.50, 30.64, 38.19, 23.85, 
40.95, 41.52, 52.76, 52.80, 58.56, 123.08, 129.34, 
133.12, 148,75, 150.68, 124.66, 127.74, 128.80, 
136.10, 142.72, 131.70, 140.56, 152.26, 165.90, 
169.60, 171.00, 175.34 (48C). MS (EI, 70 eV): m/z 
(%) = 887 (16) [M]
+
. C48H58N10O7 (887.06): Calcd. C 
64.99, H 6.59, N 15.79; found C 64.88, H 6.52, N 
15.68. 
6c:Yield 72%; m.p. 212-214°C. []
25
D
 = - 96 (c = 
0.5, DMF). IR (film): ν = 3458-3350 (NH), 1652, 
1532, 1233 (3 C=O, amides) cm
-1
. 
1
H NMR: δ = 0.88-
0.94 (m, 12H, 4CH3), 1.20-1.30 (m, 4H, 2CH2), 1.55-
1.68 (m, 4H, 2 CH2), 2.23-2.30 (m, 2H, 2CH), 3.22-
3.26 (m, 2H, CH2), 3.44 (d, 4H, 2CH2), 4.00-4.12 (m, 
4H, 4CH), 4.40-4.46 (m, 1H, CH), 7.10-7.34 (m, 10H, 
2Ph-H), 7.86-8.52 (m, 5H, pyr-H + CH=N),8.56, 9.16 
(2s, 3H, pyr-H), 8.56, 8.74, 8.80, 9.42 (4s, 7H, 7 NH, 
D2Oexchangeable). 
13
C NMR: δ = 17.60, 17.92, 
28.46, 30.50, 38.12, 23.90, 40.96, 41.50, 52.40, 52.56, 
58.52, 119.78, 144.00, 149,05, 124.87, 127.68, 
128.75, 136.18, 144.65, 131.70, 140.56, 152.26, 
165.60, 169.24, 170.56, 175.42 (48C). MS (EI, 70 eV): 
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m/z (%) = 886 (42) [M-1]
+
. C48H58N10O7 (887.06): 
Calcd. C 64.99, H 6.59, N 15.79; found C 64.90,  
H 6.5o, N 15.70. 
 
Biological Activities  
 
5α-Reductase inhibitors 
The experimental method which was used in 5α-
reductase inhibitors assay has been adopted from 
Farghaly et. al.,2012
19
 (Fig. 1) 
 
Anti-prostate cancer screening anti-androgenic bioassay in 
human prostate cancer cells 
The experimental method which was used in 5α-
reductase inhibitors assay has been adopted from 
Yuet.al., 2018
20
. 
 
Results and Discussion 
 
Chemistry 
In the present work, some of newly synthesized 
macrocyclic pentapeptide derivatives 2-6 were 
obtained by using cyclo penta-peptide hydrazide  
2 and N
α
-dinicotinoyl-bis[L-phenylalaninyl-L-leucyl] 
hydrazide 1 as starting materials, which were 
synthesized from 3,5-pyridinedicarbonyl chloride, 
according to the previous reported procedures
17
. 
Cyclization of 1 with diaminoalkanes by azide 
method or with 3,5-diacetylpyridine in refluxing 
acetic acid afforded the corresponding cyclohexaa-
zahexacarboxamide pyridines 3a-c and bicycle-
pyridine derivative 4. Condensation of hydrazide 2 
with substituted aromatic or heterocyclic aldehydes 
afforded the corresponding Schiff base derivatives 5a-
c and 6a-c, respectively (Scheme 1). 
 
Biological Screening 
A pentapeptide (Ile-Leu-Tyr-Met-Pro; ILYMP) 
was isolated from the protein hydrolysate of Cyclina 
sinensis was named Cyclina sinensis pentapeptide 
(CSP) and it was found to inhibit DU-145 cell 
proliferation at a half-maximal inhibitory concentration 
of 11.25 mM at a 72 h time interval
20
. ILX651 is a 
pentapeptide has potential for activity across a wide 
number of solid tumors. ILX651 in vitro cytotoxicity 
was recently assessed against the NCI panel 
consisting of 60 human tumor cell lines
21-23
. Cytotoxicy 
observed across the breadth of tumors tested 
(melanoma, NSCLC, prostate, breast, colon, CNS, 
and leukemia) with GI50’s ranging from <10 nM to 
>1mM. The in vivo antitumor efficacy of ILX651  
was assessed against human MX-1 breast tumor  
 
 
Fig. 1 — 5α-Reductase inhibitors activities and anti-proliferative 
activity against prostate different cancer cell lines 
 
 
 
Scheme 1 — Synthetic routes for compounds 2, 3a-c, 4, 5a-cand 
6a-c 
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with different dosages, treatment schedules, and 
administration routes.  
 
5α-Reductase inhibitors 
The newly synthesized compounds were screened 
for their 5α-reductase inhibitors activities in vivo and 
the obtained results showed potent 5α-reductase 
inhibitors activities. The descending order of 5α-
Reductase inhibitor activities was as follow: 6a, 6b, 
6c, 5a, 5b, 5c, 3a, 3b, 3c. 
 
Anti-proliferate activity against prostate cancer cell lines 
The obtained high potent 5α-reductase inhibitors 
activities encouraged the authors to identify their anti-
prostate cancer in vitro using two prostate cell lines 
namely, LNCaP and PC-3 aiming at reaching a drug 
that combine both 5α-reductase inhibitors activities 
and anti-prostate cancer activities. All the tested 
compounds were screened as anti-tumor activities in 
two prostate cell lines namely, LNCaP and PC-3.  
The descending order of anti-tumor activities in  
two prostate cell lines was as follow: 6a, 6b, 6c, 5a, 
5b, 5c, 3a, 3b, 3c. 
 
Conclusion 
All the tested compounds showed potent  
5α-reductase inhibitors activities and 5α-reductase 
inhibitors activities. The descending order of activities 
was as follow: 6a, 6b, 6c, 5a, 5b, 5c, 3a, 3b, 3c. 
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